Emerging research suggest this peptide, a dual activator targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , may offer a promising step forward for weight treatment. Preliminary human trials have shown substantial reductions in body mass , possibly exceeding existing obesity medications . However , further study is